An in vivo evaluation of nanoparticles derivatized with the CD47 ‘self-peptide’ showed superior accumulation in A549 tumors within 10 min of administration, followed by release of the encapsulated paclitaxel, resulting in significant tumor shrinkage compared to the conventional Cremophor EL formulation of the drug [111]. The gene discussed is CD47; the disease is neoplasm.